TY  - GEN
AU  - Campos-Parra,Alma D
AU  - Zuloaga,Carlos
AU  - Manríquez,María Eugenia Vazquez
AU  - Avilés,Alejandro
AU  - Borbolla-Escoboza,Jose
AU  - Cardona,Andrés
AU  - Meneses,Abelardo
AU  - Arrieta,Oscar
TI  - KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making
SN  - 1537-453X
PY  - 2015///0318
KW  - Adenocarcinoma
KW  - drug therapy
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Carboplatin
KW  - administration & dosage
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Cisplatin
KW  - Disease-Free Survival
KW  - ErbB Receptors
KW  - antagonists & inhibitors
KW  - Female
KW  - Genetic Markers
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Paclitaxel
KW  - Prognosis
KW  - Protein Kinase Inhibitors
KW  - Proto-Oncogene Proteins
KW  - genetics
KW  - Proto-Oncogene Proteins p21(ras)
KW  - Treatment Outcome
KW  - Vinblastine
KW  - Vinorelbine
KW  - ras Proteins
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1097/COC.0b013e318287bb23
ER  -